Back to News
Market Impact: 0.3
Annovis Gets NYSE Listing Notice; Plans To Regain Compliance
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
Annovis Bio said it received a notice of non-compliance with the NYSE's continued listing standards. The brief report provides no details on the specific standard or a remediation timeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.30
Ticker Sentiment
ANVS-0.70
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Apple may try to increase revenue by doing…something with third-party AI apps